Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (131)	3/18/1999 1:11:00 PM
From: Jim Oravetz	Read Replies (2) of 370

March 18, 1999 Dow Jones Newswires Vion Pharma Files Investigational NDA For Vector Study Dow Jones Newswires NEW HAVEN, Conn. -- Vion Pharmaceuticals Inc. (VION) filed an investigational new drug application with the Food and Drug Administration to conduct a safety trial for its Tapet vector to treat solid tumors. In a press release Thursday, Vion said the Phase I trial will investigate human clinical safety of intratumoral injections of the Tapet vectors in patients with solid tumors. The company said Tapet vectors are Salmonella bacteria that have been genetically engineered for safety and to preferentially target solid tumors over normal tissues to treat cancer. Preclinical studies indicate Tapet vectors were safe and able to suppress tumor growth in various animal models, the company said. Vion Pharmaceuticals is a biopharmaceutical company that develops and commercializes products to treat cancer and viral diseases.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next